Plain-English translation of NCT06465459 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Atrial Fibrillation research guide →This study is watching how the LAMBRE device performs after it is implanted in patients with atrial fibrillation. The LAMBRE is a small device placed inside the heart to reduce the risk of blood clots and stroke in people with this common heart rhythm disorder. Researchers will gather information from patients who receive this device to make sure it is safe and effective in real-world practice.
Atrial fibrillation increases the risk of stroke and other serious complications. While this treatment has been approved, this study exists to monitor how the device actually performs in everyday clinical practice across multiple hospitals and to identify any safety concerns that might not have been caught in earlier testing.
You likely qualify if…
You likely don't qualify if…
You will undergo the procedure to have the LAMBRE device implanted in your heart. After that, the study will collect information about your health outcomes and any complications over time through visits to the hospital and review of your medical records. This is not a treatment trial where you take a new medication—you are receiving the device as part of your clinical care, and researchers are simply tracking how you do afterward.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
France
Collaborators
Lifetech Scientific (Shenzhen) Co., Ltd.
Enrollment target
~220 participants
Started
June 2024
Primary completion
December 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in March 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Dr Xavier IRIART
Hôpital Cardiologique de Haut Lévêque
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.